scispace - formally typeset
Open AccessJournal ArticleDOI

Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern.

Reads0
Chats0
TLDR
In this article, the authors explored the antibody epitope repertoire, and virus neutralizing capacity of six hCoV-2IG batches as well as nine convalescent plasma (CP) against SARS-CoV2 and emerging variants of concern (VOC).
About
This article is published in iScience.The article was published on 2021-08-20 and is currently open access. It has received 21 citations till now. The article focuses on the topics: Neutralization & Epitope.

read more

Citations
More filters
Journal ArticleDOI

SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19.

TL;DR: In this paper, SARS-CoV-2 proteome-wide immunoprofiling of children with mild/moderate or severe coronavirus disease 2019 (COVID-19) versus multisystem inflammatory syndrome in children versus hospitalized control patients revealed differential cytokine responses, IgM/IgG-IgA diversity, antibody binding and avidity.
Journal ArticleDOI

Therapeutic monoclonal antibodies for COVID-19 management: an update

TL;DR: This review article provides insights into the basic aspects of monoclonal antibodies for the therapy of COVID-19, as well as its advancement in terms of clinical trial and current approval status.
Journal ArticleDOI

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

TL;DR: In this article , the authors measured the durability of neutralization capacity and antibody affinity maturation generated following two versus three doses of SARS-CoV-2 mRNA vaccines in naïve versus convalescent individuals (hybrid immunity) against the highly transmissible Omicron BA.1, BA.2 and BA.3 subvariants.
Journal ArticleDOI

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

TL;DR: More than three dozen antibodies or antibody combinations have been forwarded into clinical trials, including Eli Lilly's bamlanivimab and etesevimab, Regeneron's mixture of imdevimab with casirivimabs, Vir's sotrovimab (SOTV), Celltrion's regdanvimab, and Lilly's bebtelovimab as mentioned in this paper .
References
More filters
Journal ArticleDOI

Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2.

TL;DR: The authors determined the crystal structures of two antibodies, CC12.1 and CC 12.3, encoded by a common IGHV353 gene, but belonging to different clonotypes, in order to define the structural features, and to add favorable properties for RBD recognition to I GHV3-53, suggesting that SARSCoV, SARS-CoV-2, and MERS- coV are immunologically distinct.
Journal ArticleDOI

Flawed interferon response spurs severe illness.

Meredith Wadman
- 25 Sep 2020 - 
TL;DR: It is revealed that in a significant minority—14%— of a large global sample of patients hospitalized with life-threatening COVID-19, the body's interferon response has been crippled by genetic flaws or by rogue antibodies that attackinterferon itself.
Journal ArticleDOI

Viral evolution may herald new pandemic phase.

Kai Kupferschmidt
- 08 Jan 2021 - 
TL;DR: For COVID-19 researchers, this year brings a strong sense of deja vu. As in early 2020, the world is anxiously watching a virus spread in one country and trying to parse the risk for others as discussed by the authors.
Journal ArticleDOI

Convalescent plasma and hyperimmune globulin therapy in COVID-19.

TL;DR: In this article, the authors reviewed randomized controlled studies using convalescent plasma therapy and hyperimmune globulins (HIG) for the treatment of severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) caused by the recent global pandemic.
Related Papers (5)